Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Spinosad

Detailed information about Spinosad

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

To kill fleas and for the prevention and treatment of flea infestations ( Ctenocephalides felis ) for 1 month on dogs and puppies 14 weeks of age and older and 5.0 pounds or body weight or greater.

What to watch for:

  • Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian
  • Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention
  • Use with caution in breeding females
  • The safe use of TRIFEXIS in breeding males has not been evaluated
  • Use with caution in dogs with pre-existing epilepsy
  • Death (1 reports)
  • Weight loss (1 reports)
  • Vomiting (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian
  • Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention
  • Use with caution in breeding females
  • The safe use of TRIFEXIS in breeding males has not been evaluated
  • Use with caution in dogs with pre-existing epilepsy

Most reported reactions:

  • Death (1 reports)
  • Weight loss (1 reports)
  • Vomiting (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:02 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Mar 10, 2026, 10:05 AM UTC
Image coming soon
Spinosad

Spinosad

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Chewable Tablets, Tablet (Chewable)
Identifiers:
NADA: 141277 NADA: 141321 NDC Package: 58198-0042-1 NDC Package: 58198-0042-6 NDC Package: 58198-0043-1 NDC Package: 58198-0043-6 NDC Package: 58198-0044-1 NDC Package: 58198-0044-6 NDC Package: 58198-0045-1 NDC Package: 58198-0045-6 NDC Package: 58198-0046-1 NDC Package: 58198-0046-6 NDC Package: 58198-0071-1 NDC Package: 58198-0071-2 NDC Package: 58198-0072-1 NDC Package: 58198-0072-2 NDC Package: 58198-0073-1 NDC Package: 58198-0073-2 NDC Package: 58198-0074-1 NDC Package: 58198-0074-2
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention. Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention. Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
17
Reported cases
13
Serious reports
1
Species represented
2
Grouped by Body System
Digestive (2) · Vomiting, Diarrhea Skin & allergy (1) · Itching Behavior (1) · Behavioral disorder (unspecified) Effectiveness (2) · Lack of efficacy (endoparasite) - heartworm, Lack of efficacy (ectoparasite) - flea Other (11) · Weight loss, Tongue protrusion, Panting
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Dog 1
Other 1 Dog 0
Digestive 1 Dog 0
Other 1 Cat 0
Other 1 Cat 0
Other 1 Dog 0
Other 1 Dog 0
Other 1 Cat 0

Species coverage: Dog (10) Cat (7)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Other Dog Non-serious - 1
Digestive Dog Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Effectiveness Dog Non-serious - 1
Effectiveness Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Behavior Cat Non-serious - 1
Other Dog Unknown - -
Digestive Dog Unknown - -
Other Dog Unknown - -
Other Dog Unknown - -
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (2)
  • COMFORTIS N141277.pdf · Labeling
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/883
  • TRIFEXIS N141321C0060.pdf · Labeling
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/913
SPL (2)
  • Comfortis® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/214/Comfortis%C2%AE
  • Trifexis™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2207/Trifexis%E2%84%A2
FOI (3)
  • UCM326907.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/838
  • ucm062334.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/837
  • UCM252248.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/878
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Mar 10, 2026, 10:05 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Comfortis® Trifexis™
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Chewable Tablets, Tablet (Chewable) • Oral
Applications: NADA 141-277 • NADA 141-321
Documents: 5 (FOI: 3) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 23 • Cat 12 • View
Case summaries: 13 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: B74.8 ICD10_CM: B88.1
Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention. Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. (Contraindication, High)
Top reaction signals
Death (1) Weight loss (1) Vomiting (1) Tongue protrusion (1) Panting (1) Overdose (1) Malaise (1) Licking (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141277 NADA: 141321 NDC Package: 58198-0042-1 NDC Package: 58198-0042-6 NDC Package: 58198-0043-1 NDC Package: 58198-0043-6 NDC Package: 58198-0044-1 NDC Package: 58198-0044-6 NDC Package: 58198-0045-1 NDC Package: 58198-0045-6 NDC Package: 58198-0046-1 NDC Package: 58198-0046-6 NDC Package: 58198-0071-1 NDC Package: 58198-0071-2 NDC Package: 58198-0072-1 NDC Package: 58198-0072-2 NDC Package: 58198-0073-1 NDC Package: 58198-0073-2 NDC Package: 58198-0074-1 NDC Package: 58198-0074-2 NDC Package: 58198-0075-1 NDC Package: 58198-0075-2 NDC Package: 73064-0305-1 NDC Product: 58198
Package NDC Product NDC Form / Route Status
58198-0042-1 58198 -
58198-0042-6 58198 -
58198-0043-1 58198 -
58198-0043-6 58198 -
58198-0044-1 58198 -
58198-0044-6 58198 -
58198-0045-1 58198 -
58198-0045-6 58198 -
58198-0046-1 58198 -
58198-0046-6 58198 -
58198-0071-1 58198 -
58198-0071-2 58198 -
58198-0072-1 58198 -
58198-0072-2 58198 -
58198-0073-1 58198 -
58198-0073-2 58198 -
58198-0074-1 58198 -
58198-0074-2 58198 -
58198-0075-1 58198 -
58198-0075-2 58198 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • TRIFEXIS N141321C0060.pdf • Official label • Official • May 17, 2021
    FDA official labeling for application 141321
  • UCM252248.pdf • FOI summary • Official • May 17, 2021
    FDA FOI summary for application 141321
  • COMFORTIS N141277.pdf • Official label • Official • May 17, 2021
    FDA official labeling for application 141277
  • ucm062334.pdf • FOI summary • Official • May 17, 2021
    FDA FOI summary for application 141277
  • UCM326907.pdf • FOI summary • Official • May 17, 2021
    FDA FOI summary for application 141277

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 8 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law restricts this drug to use by or on the order of a lice… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy (endoparasite) - heartwor… (Official, 2026-02-12)
  • usage: To kill fleas and for the prevention and treatment of flea infestations ( Ctenocephalides felis ) for 1 month on dogs and puppies 14 weeks of age and older and… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Comfortis®
RX
Spinosad
Tablet (Chewable) • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-277 Approved May 17, 2021
Trifexis™
RX
Milbemycin Oxime Spinosad
Chewable Tablets • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-321 Approved May 17, 2021

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each chewable tablet contains 140, 270, 560, 810, or 1620 milligrams (mg) spinosad.
Dogs
Indication

To kill fleas and for the prevention and treatment of flea infestations (Ctenocephalides felis) for 1 month on dogs and puppies 14 weeks of age and older and 5.0 pounds or body weight or greater.

Dosage
Administer tablets once a month at a recommended minimum dosage of 13.5 mg per pound (30 mg per kilogram) of body weight.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication

To kill fleas and for the prevention and treatment of flea infestations (Ctenocephalides felis) for 1 month on cats and kittens 14 weeks of age and older and 4.1 pounds of body weight or greater.

Dosage
Administer tablets once a month at the minimum dosage of 22.5 mg per pound (50 mg per kilogram) of body weight.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
The product is available in five tablet strengths:
140 mg spinosad and 2.3 mg milbemycin oxime
270 mg spinosad and 4.5 mg milbemycin oxime
560 mg spinosad and 9.3 mg milbemycin oxime
810 mg spinosad and 13.5 mg milbemycin oxime
1620 mg spinosad and 27 mg milbemycin oxime
Dogs and Puppies (8 Weeks and Older and 5 Lbs or Greater)
Indication
Trifexis™ Chewable Tablets kill fleas and are indicated for the prevention and treatment of flea infestations (Ctenocephalides felis), and the treatment and control of adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis and Toxascaris leonina) and adult whipworm (Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.
Dosage
Given orally, once a month at a minimum dosage of 13.5 mg/lb (30 mg/kg) spinosad and 0.2 mg/lb (0.5 mg/kg) milbemycin oxime body weight.
Limitations
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention. Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy.
Indication
Trifexis™Chewable Tablets are indicated for the prevention of heartworm disease (Dirofilaria immitis).
Dosage
Given orally, once a month at a minimum dosage of 13.5 mg/lb (30 mg/kg) spinosad and 0.2 mg/lb (0.5 mg/kg) milbemycin oxime body weight.
Limitations
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention. Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary
    1) To add an indication for use in cats: Kills fleas and is indicated for the prevention and treatment of flea infestations (Ctenocephalides felis) for one month in cats and kittens 14 weeks of age and older, and two pounds of body weight or greater, and 2) add the 90 mg dose band for use of Comfortis® in dogs.
  • Summary
    Kill fleas and are indicated for the prevention and treatment of flea infestations ( Ctenocephalides felis) on dogs for one month.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    Indicated for the prevention of heartworm disease ( Dirofilaria immitis). Trifexis™ Chewable Tablets kill fleas and are indicated for the prevention and treatment of flea infestations ( Ctenocephalides felis), and the treatment and control of adult hookworm ( Ancylostoma caninum), adult roundworm ( Toxocara canis and Toxascaris leonina) and adult whipworm ( Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

To kill fleas and for the prevention and treatment of flea infestations ( Ctenocephalides felis ) for 1 month on dogs and puppies 14 weeks of age and older and 5.0 pounds or body weight or greater. To kill fleas and for the prevention and treatment of flea infestations ( Ctenocephalides felis ) for 1 month on cats and kittens 14 weeks of age and older and 4.1 pounds of body weight or greater. Trifexis™ Chewable Tablets kill fleas and are indicated for the prevention and treatment of flea infestations ( Ctenocephalides felis ), and the treatment and control of adult hookworm ( Ancylostoma caninum ), adult roundworm ( Toxocara canis and Toxascaris leonina ) and adult whipworm ( Trichuris vulpis ) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Treatment with fewer than 3 monthly doses after the last exposure to mosquitos may not provide complete heartworm prevention. Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Diarrhea • Dog

Showing top 5 for Digestive.

Skin & allergy
Itching (1) • Cat

Showing top 5 for Skin & allergy.

Behavior
Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Effectiveness
Lack of efficacy (endoparasite) - heartworm (1) • Dog Lack of efficacy (ectoparasite) - flea (1) • Cat

Showing top 5 for Effectiveness.

Other
Weight loss (1) • Dog Tongue protrusion (1) • Cat Panting (1) • Cat Overdose (1) • Dog Malaise (1) • Dog
Show more (6)
Licking (1) • Cat Hyperactivity (1) • Cat Death (1) • Dog Drug dose omission • Dog Arthritis • Dog Administration error NOS • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Crossbred Canine/dog, Female, 11 year, 26.2 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 810 Milligram per animal • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055803
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 26.200 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 810 Milligram per animal
Reactions Reported:
Lack of efficacy (endoparasite) - heartworm
Outcomes: Outcome Unknown

Dog, Terrier - Yorkshire, Female, 9.25 year, 3.76 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 dose per animal, Frequency: 1 per month • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-056111
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 9.25 Year
  • Weight: 3.760 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1 dose per animal
  • Frequency: 1 per month
Reactions Reported:
Lack of efficacy (endoparasite) - heartworm
Outcomes: Outcome Unknown

Dog, ['Shepherd Dog - German', 'Dog (unknown)'], Male, 7.92 year • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal, Frequency: 1 per month • Reactions: Lack of efficacy (endoparasite) - heartworm, Weight loss • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055771
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 7.92 Year
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1 tablet per animal
  • Frequency: 1 per month
Reactions Reported:
Lack of efficacy (endoparasite) - heartworm Weight loss
Outcomes: Outcome Unknown

Dog, ['Spaniel - King Charles Cavalier', 'Poodle (unspecified)'], Female, 3 year, 5.52 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 270 Milligram per animal • Reactions: Vomiting, Malaise • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-054540
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 5.520 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 270 Milligram per animal
Reactions Reported:
Vomiting Malaise
Outcomes: Outcome Unknown

Dog, Dog (unknown), Unknown • Drug: MSK, Tablet, chewable, Oral, Dose: 1620 Milligram per animal • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055630
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1620 Milligram per animal
Reactions Reported:
Death
Outcomes: Died

Dog, Pit Bull, Male, 1.24 year, 27.21 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1620 Milligram per animal • Reactions: Vomiting, Overdose • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055811
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 1.24 Year
  • Weight: 27.210 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1620 Milligram per animal
Reactions Reported:
Vomiting Overdose
Outcomes: Recovered/Normal

Dog, Retriever - Labrador, Female, 4 year, 32.2 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal, Frequency: 1 per month • Reactions: Vomiting • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-054533
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 4.00 Year
  • Weight: 32.200 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1 tablet per animal
  • Frequency: 1 per month
Reactions Reported:
Vomiting
Outcomes: Recovered/Normal

Dog, Dog (unknown), Unknown • Drug: MSK, Tablet, chewable, Oral, Dose: 1620 Milligram per animal, Frequency: 1 per month • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055624
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1620 Milligram per animal
  • Frequency: 1 per month
Reactions Reported:
Death
Outcomes: Died

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.